[ConMed] Shareholder Meeting Resolution Passed to Waive Non-compete Restrictions for Director
ConMed Biotech held a general shareholder meeting on May 22, 2026, and approved the resolution to waive non-compete restrictions for independent director Luo Bao-zhu, allowing her to serve concurrently as an independent director at Ouro International Biotech and PharmaEngine.
📋 Article Processing Timeline
- 📰 Published: May 22, 2026 at 09:00
- 🔍 Collected: May 23, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 24, 2026 at 06:07 (22h 7m after Collected)
1. Date of shareholder meeting resolution: May 22, 2026
2. Name and title of the director permitted to engage in competitive behavior:
(1) Independent Director: Luo Bao-zhu
3. Items permitted for competitive behavior:
Independent Director Luo Bao-zhu holds concurrent positions as:
Independent Director at Ouro International Biotech Co., Ltd.
Independent Director at PharmaEngine, Inc.
4. Period of permitted competitive behavior: During the term of office as an independent director of the company.
5. Voting results (pursuant to Article 209 of the Company Act):
In accordance with Article 209 of the Company Act, the resolution was passed with the attendance of shareholders representing at least two-thirds of the total issued shares, with the approval of more than half of the voting rights of the attending shareholders.
6. Name and title of the director if the competitive behavior relates to business in Mainland China:
(If not related to business in Mainland China, please enter "Not applicable"): Not applicable.
7. Company name and position held in the Mainland China business: Not applicable.
8. Address of the Mainland China business: Not applicable.
9. Business scope of the Mainland China business: Not applicable.
10. Impact on the company's financial and business operations: Not applicable.
11. Amount of investment and shareholding ratio if the director has invested in the Mainland China business: Not applicable.
12. Other matters: None.
2. Name and title of the director permitted to engage in competitive behavior:
(1) Independent Director: Luo Bao-zhu
3. Items permitted for competitive behavior:
Independent Director Luo Bao-zhu holds concurrent positions as:
Independent Director at Ouro International Biotech Co., Ltd.
Independent Director at PharmaEngine, Inc.
4. Period of permitted competitive behavior: During the term of office as an independent director of the company.
5. Voting results (pursuant to Article 209 of the Company Act):
In accordance with Article 209 of the Company Act, the resolution was passed with the attendance of shareholders representing at least two-thirds of the total issued shares, with the approval of more than half of the voting rights of the attending shareholders.
6. Name and title of the director if the competitive behavior relates to business in Mainland China:
(If not related to business in Mainland China, please enter "Not applicable"): Not applicable.
7. Company name and position held in the Mainland China business: Not applicable.
8. Address of the Mainland China business: Not applicable.
9. Business scope of the Mainland China business: Not applicable.
10. Impact on the company's financial and business operations: Not applicable.
11. Amount of investment and shareholding ratio if the director has invested in the Mainland China business: Not applicable.
12. Other matters: None.
FAQ
What is ConMed Biotech's governance approach?
The company maintains high governance standards by transparently managing concurrent roles for independent directors through shareholder approval.
What does this resolution mean?
It is a formal approval process allowing an independent director to serve on multiple boards, fostering industry-wide knowledge sharing.
What is a non-compete restriction?
It prevents directors from engaging in activities that conflict with the company's interests; it was waived here following proper procedure.